Last reviewed · How we verify
"Usual Care"
Usual Care is not a drug but rather a control or comparator arm representing standard clinical management without the investigational intervention.
At a glance
| Generic name | "Usual Care" |
|---|---|
| Sponsor | Novartis |
| Modality | Small molecule |
| Phase | FDA-approved |
Mechanism of action
Usual Care serves as a benchmark in clinical trials to measure the efficacy and safety of an investigational drug against the existing standard of treatment. It encompasses whatever therapeutic approaches, medications, or management strategies are currently considered standard practice for a given condition, allowing researchers to determine whether the new drug provides additional clinical benefit.
Approved indications
Common side effects
Key clinical trials
- Clinical Outcome and Cost-effectiveness of Reduced Noradrenaline by Using a Lower Blood Pressure Target in Patients With Cardiogenic Shock From Acute Myocardial Infarction (PHASE4)
- Creating Access to Resources and Economic Support (NA)
- "Improving Health and Reducing Chronic Disease Risk in Middle-Aged Adults Through Nutrition" (NA)
- Shared Decision-Making Decision Aid for Newly Diagnosed Breast Cancer : A Multi-Center Randomized Controlled Trial (NA)
- Reducing Symptom Burden Through Physical Exercise in Melanoma Patients (NA)
- Bedside Bike Early Mobilization Program for Inpatients (NA)
- Dyadic Management Intervention in Older People With Co-occurring Cognitive Impairment and Diabetes as a Supplementary Approach to Chronic Diseases Self-Management Program (NA)
- Living With Multimorbidity: Care Coordination and Symptom Management Program (COORDINATE) (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- "Usual Care" CI brief — competitive landscape report
- "Usual Care" updates RSS · CI watch RSS
- Novartis portfolio CI